Beta Drugs マネジメント
マネジメント 基準チェック /44
Beta Drugsの CEO はRahul Batraで、 Jan2021年に任命され、 の在任期間は 3.83年です。 の年間総報酬は₹ 12.10Mで、 100%給与と0%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.41%を直接所有しており、その価値は₹ 84.99M 。経営陣と取締役会の平均在任期間はそれぞれ3.8年と7.3年です。
主要情報
Rahul Batra
最高経営責任者
₹12.1m
報酬総額
| CEO給与比率 | 100.0% |
| CEO在任期間 | 3.8yrs |
| CEOの所有権 | 0.4% |
| 経営陣の平均在職期間 | 3.8yrs |
| 取締役会の平均在任期間 | 7.3yrs |
経営陣の近況
Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹410m |
| Jun 30 2024 | n/a | n/a | ₹387m |
| Mar 31 2024 | ₹12m | ₹12m | ₹364m |
| Dec 31 2023 | n/a | n/a | ₹356m |
| Sep 30 2023 | n/a | n/a | ₹348m |
| Jun 30 2023 | n/a | n/a | ₹327m |
| Mar 31 2023 | ₹12m | n/a | ₹307m |
| Dec 31 2022 | n/a | n/a | ₹298m |
| Sep 30 2022 | n/a | n/a | ₹289m |
| Jun 30 2022 | n/a | n/a | ₹269m |
| Mar 31 2022 | ₹8m | ₹8m | ₹248m |
| Dec 31 2021 | n/a | n/a | ₹216m |
| Sep 30 2021 | n/a | n/a | ₹183m |
| Jun 30 2021 | n/a | n/a | ₹150m |
| Mar 31 2021 | ₹6m | ₹6m | ₹117m |
| Dec 31 2020 | n/a | n/a | ₹106m |
| Sep 30 2020 | n/a | n/a | ₹95m |
| Jun 30 2020 | n/a | n/a | ₹94m |
| Mar 31 2020 | ₹5m | ₹5m | ₹94m |
| Sep 30 2019 | n/a | n/a | ₹97m |
| Jun 30 2019 | n/a | n/a | ₹89m |
| Mar 31 2019 | ₹1m | ₹1m | ₹80m |
報酬と市場: Rahulの 総報酬 ($USD 143.26K ) は、 Indian市場 ($USD 187.40K ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Rahulの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Rahul Batra (41 yo)
3.8yrs
在職期間
₹12,100,000
報酬
Mr. Rahul Batra serves as the Chairman & Managing Director of Beta Drugs Limited since January 27, 2021. He had been Whole Time Director of Beta Drugs Limited since August 1, 2014 until January 27, 2021. H...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & MD | 3.8yrs | ₹12.10m | 0.41% ₹ 85.0m | |
| Joint MD & Whole Time Director | 3.8yrs | ₹12.10m | 0.35% ₹ 71.2m | |
| Chief Financial Officer | 3.7yrs | ₹3.10m | データなし | |
| Company Secretary & Compliance Officer | 7.3yrs | ₹911.55k | データなし | |
| VP of Sales & Marketing and Whole Time Director | 5.7yrs | ₹5.12m | データなし | |
| Whole Time Director | no data | ₹1.19m | データなし | |
| Vice President of Technical | no data | データなし | データなし |
3.8yrs
平均在職期間
40.5yo
平均年齢
経験豊富な経営陣: BETAの経営陣は 経験豊富 であると考えられます ( 3.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman & MD | 10.3yrs | ₹12.10m | 0.41% ₹ 85.0m | |
| Joint MD & Whole Time Director | 10.3yrs | ₹12.10m | 0.35% ₹ 71.2m | |
| VP of Sales & Marketing and Whole Time Director | 2.8yrs | ₹5.12m | データなし | |
| Whole Time Director | 5.3yrs | ₹1.19m | データなし | |
| Independent Director | 7.3yrs | データなし | データなし | |
| Independent Director | 7.3yrs | データなし | データなし |
7.3yrs
平均在職期間
48yo
平均年齢
経験豊富なボード: BETAの 取締役会 は 経験豊富 であると考えられます ( 7.3年の平均在任期間)。